🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Rafael Holdings, Inc. (RFL)
NYSE: RFL · Real-Time Price · USD
0.9871
+0.0737 (8.07%)
Nov 18, 2026, 4:00 PM EST - Market closed
← View all transcripts

3rd Annual Guggenheim Healthcare Innovation Conference

Nov 9, 2026

Summary

The pivotal Phase III missed its primary endpoint, but subgroup, infantile and survival findings supported an October NDA filing for remibetadex. FDA day-60 feedback is expected Dec. 27; with priority review, PDUFA is targeted for June next year.

Eddie Hickman
Analyst, Guggenheim

minutes late here. Sorry about that. Welcome back to the Guggenheim Healthcare Innovation Conference here in Boston. My name is Eddie Hickman. I am one of the healthcare analysts here at Guggenheim. Today, I am joined by several members of the Rafael Holdings team. We have Josh and Mike. Gentlemen, thank you so much for being here. Appreciate your time. Maybe before we get started, just for anyone who is not familiar with the company, maybe just give us a five-minute overview of sort of the history of the company and what brings you here today.

Joshua Fine
COO, Rafael Holdings

Sure. Thank you.

Eddie Hickman
Analyst, Guggenheim

Take a breath first.

Joshua Fine
COO, Rafael Holdings

Yeah, no, it is a good run. Thank you for hosting us, Eddie, and thank you to Guggenheim for hosting us as well. We appreciate it. We are happy to be here. So, real quick on Rafael Holdings Cyclo Therapeutics. The two companies came together in March of 2025. At that point in time, Rafael had actually been the largest investor in Cyclo Therapeutics. Cyclo Therapeutics, which is where we are going to focus most of our time and most of the questions on, I believe, today, has actually been around since the 1990s.

But in 2014 and 2015, they launched their study on Trappsol Cyclo for the treatment of Niemann-Pick type C. Over the last now 10+ years, we have completed our phase I, phase I/II, and we just completed our pivotal phase III study for the treatment of the neurovisceral manifestations of Niemann-Pick type C from adult to birth.

That study completed in June of this year. In September, we reported out our top-line data on our pivotal study, and at the end of last month, we submitted our NDA to the FDA for what is now called remibetadex for the treatment of Niemann-Pick type C. We are predominantly an R&D company at this point in time, but our plan is to commercialize the asset and launch it here in the States. That is us in a nutshell.

Eddie Hickman
Analyst, Guggenheim

Great. Yeah, thanks for that. Let us start with remibetadex and the study. Tell us a little bit about the design of the study, the choice of these endpoints, and then what you showed.

Joshua Fine
COO, Rafael Holdings

Sure. I am going to start this one off and then pass it over to you.

Eddie Hickman
Analyst, Guggenheim

Yeah, absolutely.

Joshua Fine
COO, Rafael Holdings

The study kicked off in 2021. It was a two-year, 94-patient double-blind study with a 48-week interim look. That study design was actually done collectively and fairly collaboratively with the FDA, who wanted us to extend out our study for two years as a result of what we think were some of the things that they were seeing in the industry at the time. The endpoints

Mike Lisjak
Chief Regulatory Officer, Cyclo Therapeutics

Yeah. The endpoints are the composite score of the 4D, which is swallow, ambulation, fine motor, and speech. These endpoints were developed with the FDA based on their feedback of previous other molecules that they were looking at. During the kickoff of our phase III trial, not only did we add that as a primary endpoint, but we also looked at Trappsol Cyclo against standard of care and placebo against standard of care, which is important. Part of what we did in the development of that is, in order to participate in the study, miglustat was also being used at this time as a standard of care for both placebo and Trappsol. Those patients that came in had to be on background miglustat for three months as part of coming into entry of the study.

When you think collectively as our program worked out in our specification, our pre-specified covariate with the FDA, it was done with purpose at the beginning of the study.

Eddie Hickman
Analyst, Guggenheim

You missed on the primary, but you obviously felt confident with filing. Just walk us through the decision-making process from what you saw in that study that excited you about moving forward.

Mike Lisjak
Chief Regulatory Officer, Cyclo Therapeutics

Yeah, sure.

Joshua Fine
COO, Rafael Holdings

As Mike said, and as you stated, we missed on our primary. The pre-specified covariate that we saw was actually an incredibly exciting moment for us. It represented a very large portion of our patient population, and as Mike said, the clarity was that it was all patients were either on remibetadex miglustat or placebo and miglustat. The patient population itself was large enough to get us excited. Additionally, as we looked at some of the underlying data, we saw some pretty compelling trends in the individual domains, and then as we've also published, the sub-study data from the 0 to three patient population was incredibly influential and incredibly exciting. As we've noted, at 48 weeks, we saw eight of 10 patients either stabilize or improvement, and this is a patient population that is the most severely affected.

At SSIEM, we presented data where seven of six patients had completed 96 weeks, and six of those patients had still either stabilized or improved. You tie that into the overall survival analysis that we did as further supportive evidence, where we actually have two p-values. We felt pretty compelled and pretty excited about what was going on, and then the ongoing interaction with the FDA, making sure they were looped into what was going on inside the company, gave us confidence and drove us to get this NDA in.

Mike Lisjak
Chief Regulatory Officer, Cyclo Therapeutics

Yeah. I think through our pre-NDA meeting that we had with the FDA in February and talking about this as we were kind of looking through our data on what we were doing. The interesting thing, Eddie, that you said about the pre-specified and the primary missing, if you look at those cohorts specifically, whether it was on the full data cohort of 94 patients or the 78 that were part of just the subgroup of the covariate analysis, the Trappsol group itself showed a 0.46 over the two year, and that was consistent across both the overall 94 patients as well as the 78 patients. So that also gave us compelling idea to go to the FDA with totality of data.

And then as Josh said, with responder analysis, the sub-study analysis, the overall survival, we feel we had a totality of data package that the FDA has looked at with other companies as far as regulatory flexibility that we feel confident with.

Eddie Hickman
Analyst, Guggenheim

Yeah. So another recent approval in the space has on their label similar, where it is like with background miglustat. Obviously, you had some leucine patients as well. Is that the idea? Is that the ideal label would be sort of on top of whatever standard of care is for these patients?

Joshua Fine
COO, Rafael Holdings

No. Our goal is obviously to get a drug to these patients, but the label that we, or the indication in the label that we went for is the neurovisceral manifestations of Niemann-Pick type C from adult and pediatrics from birth and above as a monotherapy. And again, to Mike's point and now to that point, for clarity, the leucine was the over-the-counter drug that is available in some European countries. Wanted to make that known as well. But I think that to Mike's point about the 0.46 in both treatment groups, we feel pretty strongly that it was Trappsol or remibetadex that was having the effect on the disease. And that goes back, and again, to the even in the pre-specified subgroup, both miglustat was used in both placebo group and the treatment group.

Across the board, to Mike's point, the Trappsol group, we feel responded very well to this at a 0.46 decline at two years.

Eddie Hickman
Analyst, Guggenheim

Do you expect that to be different? Because obviously your age range is much broader.

Joshua Fine
COO, Rafael Holdings

Mm-hmm. Yeah.

Eddie Hickman
Analyst, Guggenheim

So, like is the expectation that given what you've shown, the effect is sort of similar across patients, or do you expect a different effect in more severe patients?

Joshua Fine
COO, Rafael Holdings

No, so I don't think so. I think that our goal is to focus on the broad range of patients, and as we disseminate our data and talk to the FDA, we'll focus on it. But I think the data, to your point, Eddie, this study treated collectively inclusive of the sub-study from seven months to 58, 60 years old?

Eddie Hickman
Analyst, Guggenheim

68.

Joshua Fine
COO, Rafael Holdings

68 years old. The totality of data for us, I think, supports, hopefully supports the label being as broad as we can and the indication treating this disease, even though the variability is there across the board.

Eddie Hickman
Analyst, Guggenheim

Is this a-- Because you filed recently.

Is this something that you'd expect there to be an AdCom or some sort of other FDA review process because of the way the primary endpoint went?

Joshua Fine
COO, Rafael Holdings

I think we are prepared for all situations with the expectation that we don't have or won't have an AdCom.

Eddie Hickman
Analyst, Guggenheim

What about this infantile study? Like, where does that fit in the open label patients? Would that be something that the FDA would see before approval or that—

Joshua Fine
COO, Rafael Holdings

They've seen it. It was part of the submission.

Eddie Hickman
Analyst, Guggenheim

They've got it. Okay.

Joshua Fine
COO, Rafael Holdings

Yep.

Eddie Hickman
Analyst, Guggenheim

Yep. They have everything and there's like no more. Are patients still being treated as part of the open label extension?

Joshua Fine
COO, Rafael Holdings

Not only the open label extension, Eddie, but we actually have patients rolling off of the OLE, which puts them in or around the study for four years and onto an EAP program. We have study patients, we have patients that are still enrolled, they are still being treated by remibetadex that have gone out up to six years now.

Eddie Hickman
Analyst, Guggenheim

Is this something that, if we see an approval potentially sometime next year, how do you, in your conversations with physicians in the space, how would this be used in conjunction with other approved therapies? Is this something that can be added on? Is this something that severe patients would just take, throw everything at them, or do you see a differentiation from what arimoclomol is doing?

Joshua Fine
COO, Rafael Holdings

We see it is an ultra-rare disease with two approved therapies and a third therapy that is being used in the U.S. here. I do not want to say it is going to be additive. We see that it will be used. Our goal is that zero to three patient population. We think that we hopefully, the goal would be to be their option, finally a real option for them. As it relates to everything else, we do not see patients coming off the drugs that they are currently on. That will be a physician decision. We see this most likely being an additive to that, and it will be a patient and caregiver decision as to what they choose to use. We know that we have not seen any DDI. We have not had any DDI issues with any of the other treatments so far.

Eddie Hickman
Analyst, Guggenheim

What does the commercial outlook look like when you have, like I said, other approved options? How do you think about pricing and how do you think about like where to go first? Are these your low-hanging fruit? Obviously, you know certain low-hanging fruit with the younger patients potentially, but how do you think about the best way to commercialize this going forward?

Joshua Fine
COO, Rafael Holdings

So, you hit the nail partially right on the head, Eddie, which was focusing, and we're very active right now with some of the patient groups and working with them on newborn screening. That's very important to us as we look to find a way to diagnose this more frequently. We feel that there is a giant void in that space right now across the board. Related to commercially and pricing, I think the fact that we are third to market helps us because they've set a fairly competitive range. We feel like that's a very good comparator for us to fall into. Our goal, like I said, what sets us apart as a treatment is that we would be the only drug on market that treats the neurovisceral symptomology of the disease.

Everything else is really focused on the neurological symptomology of the disease, which could potentially get us a stronger or higher price point.

Eddie Hickman
Analyst, Guggenheim

Got it. Now, does that have any—e ven if, let's say it was an equal price point, does the fact that this is a different mode of administration being IV versus an oral change the way you think about the pricing potential?

Joshua Fine
COO, Rafael Holdings

No. I don't think we've taken that into account when we've had discussions, no.

Eddie Hickman
Analyst, Guggenheim

Got you. What about outside the U.S.? Obviously, we know that there's a pretty established NPC population, maybe larger even than in the U.S., in Europe and beyond. So, obviously a different regulatory agency, different bars. Does this application sort of click over, and is it applicable for the EMA?

Joshua Fine
COO, Rafael Holdings

The EMA has a different primary. They were the 5D where the U.S. was the 4D. I think from a regulatory standpoint, we are very excited about the rest of the world. Our plans are to start working through that process sometime early first half next year, with Mike and his team leading the regulatory pathways there. Commercially, we view it not as similar to the U.S., but most likely we would find a partner for this asset. What does set us apart is the fact that we recruited 104 patients, and a lot of them were in the European countries.

Mike Lisjak
Chief Regulatory Officer, Cyclo Therapeutics

Yeah.

Okay.

One thing else also to add is with the European market, we've also had scientific advice meetings. We've been engaged with the EMA. The sub-study, the 0 to three patient population, is a requirement for the pediatric investigational plan. That's a requirement in the E.U., and so that data is going to be part of that package as well. So everything that we've done for the U.S. is congruent with what the EMA expectations would be.

Eddie Hickman
Analyst, Guggenheim

Yeah, very helpful today. Just remind us before we end, sort of the key timelines to look forward to over the next sort of six months.

Joshua Fine
COO, Rafael Holdings

Sure. We're very proud of our team, so we're going to start backwards. In June of this year, we announced last patient, last visit in our pivotal phase III study for the 94th patient hitting the 96th week. In September, we announced our top line data set. In October, we submitted our NDA. We anticipate hearing back from the FDA on day 60, would be December 27th. Assuming they grant us priority review or potential for priority review, PDUFA would be June of next year.

Eddie Hickman
Analyst, Guggenheim

Yeah. We'll see what the Christmas holiday has.

Joshua Fine
COO, Rafael Holdings

Yeah. We're very excited about Christmas.

Eddie Hickman
Analyst, Guggenheim

I want to ask just about the financial positioning. Obviously, it's a targeted launch in an ultra-rare population, but how much do you need to have to be comfortable with a U.S. launch, and what does your cash position look like?

Joshua Fine
COO, Rafael Holdings

Our calendar year ends, fiscal year ends July. At the end of July, we had just over $22 million in cash. That gives us just under a 12-month run rate, give or take. We can stretch it out. The goal right now is we believe we have enough capital to get us through the PDUFA date, and then we would need not a substantial amount of money. It's a few million dollars extra to really build out the team and the infrastructure to commercially launch the drug in the United States.

Eddie Hickman
Analyst, Guggenheim

Just to verify, I think you said this, but I may have missed it. You're expecting standard review, or is there a possibility for accelerated?

Joshua Fine
COO, Rafael Holdings

We're accepting a priority review, so six months.

Eddie Hickman
Analyst, Guggenheim

Six months. Okay.

Joshua Fine
COO, Rafael Holdings

Yeah.

Eddie Hickman
Analyst, Guggenheim

Potentially, yeah, you said May or June.

Joshua Fine
COO, Rafael Holdings

Yep.

Mike Lisjak
Chief Regulatory Officer, Cyclo Therapeutics

Yep.

Eddie Hickman
Analyst, Guggenheim

Potentially. Very good. That's all I have. Thank you so much for being here. Appreciate the time.

Mike Lisjak
Chief Regulatory Officer, Cyclo Therapeutics

Yeah.

Joshua Fine
COO, Rafael Holdings

Sorry we're late.

Eddie Hickman
Analyst, Guggenheim

No, no. I think we got through it all.

Mike Lisjak
Chief Regulatory Officer, Cyclo Therapeutics

Yeah, sorry we were late. Thanks.

Eddie Hickman
Analyst, Guggenheim

We got through it all. Thanks for being here.

Joshua Fine
COO, Rafael Holdings

Excellent.

Eddie Hickman
Analyst, Guggenheim

Thanks.